Department of Ophthalmology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, China.
Stem Cell Res Ther. 2022 Jun 3;13(1):228. doi: 10.1186/s13287-022-02889-x.
Corneal transplantation is the only way to treat serious corneal diseases caused by corneal endothelial dysfunction. However, the shortage of donor corneal tissues and human corneal endothelial cells (HCECs) remains a worldwide challenge. We cultivated HCECs by the use of a conditioned medium from orbital adipose-derived stem cells (OASC-CM) in vitro. Then the HCECs were used to treat animal corneal endothelial dysfunction models via cell transplantation. The purpose of this study was to conduct a long-term observation and evaluation after cell transplantation.
Orbital adipose-derived stem cells (OASCs) were isolated to prepare the conditioned medium (CM). HCECs were cultivated and expanded by the usage of the CM (CM-HCECs). Then, related corneal endothelial cell (CEC) markers were analyzed by immunofluorescence. The cell proliferation ability was also tested. CM-HCECs were then transplanted into monkey corneal endothelial dysfunction models by injection. We carried out a 24-month postoperative preclinical observation and verified the long-term effect by histological examination and transcriptome sequencing.
CM-HCECs strongly expressed CEC-related markers and maintained polygonal cell morphology even after 10 passages. At 24 months after cell transplantation, there was a CEC density of more than 2400 cells per square millimeter (range, 2408-2685) in the experimental group. A corneal thickness (CT) of less than 550 μm (range, 490-510) was attained. Gene sequencing showed that the gene expression pattern of CM-HCECs was similar to that of transplanted cells and HCECs.
Transplantation of CM-HCECs into monkey corneal endothelial dysfunction models resulted in a transparent cornea after 24 months. This research provided a promising prospect of cell-based therapy for corneal endothelial diseases.
角膜移植是治疗由角膜内皮功能障碍引起的严重角膜疾病的唯一方法。然而,供体角膜组织和人角膜内皮细胞(HCEC)的短缺仍是全球性挑战。我们使用眼眶脂肪来源干细胞(OASC)的条件培养基在体外培养 HCEC,然后通过细胞移植将 HCEC 用于治疗动物角膜内皮功能障碍模型。本研究旨在进行细胞移植后的长期观察和评估。
分离眼眶脂肪来源干细胞(OASC)制备条件培养基(CM)。使用 CM 培养和扩增 HCEC(CM-HCEC)。然后,通过免疫荧光分析相关角膜内皮细胞(CEC)标志物。还测试了细胞增殖能力。通过注射将 CM-HCEC 移植到猴角膜内皮功能障碍模型中。我们进行了 24 个月的术后临床前观察,并通过组织学检查和转录组测序验证了长期效果。
CM-HCEC 强烈表达 CEC 相关标志物,即使经过 10 代培养仍保持多边形细胞形态。细胞移植后 24 个月,实验组每平方毫米的 CEC 密度超过 2400 个细胞(范围 2408-2685 个)。角膜厚度(CT)小于 550μm(范围 490-510μm)。基因测序显示,CM-HCEC 的基因表达模式与移植细胞和 HCEC 相似。
将 CM-HCEC 移植到猴角膜内皮功能障碍模型中,24 个月后可获得透明角膜。这项研究为角膜内皮疾病的细胞治疗提供了有前途的前景。